| 股票代码 | 600276 | 当期评分 | ||||
| 股票名称 | 恒瑞医药 | |||||
| 报告日期 | 2018-12-31 | 2019-12-31 | 2020-03-31 | 2020-06-30 | 2020-09-30 | 2020-09-30 |
| 每股经营现金流(¥) | 0.7534 | 0.863 | 0.349 | 0.6363 | 0.7512 | ✘ |
| 销售净利润率(%) | 23.3162 | 22.8715 | 23.627 | 23.455 | 21.855 | ✔ |
| 销售毛利率(%) | 85.2373 | 86.563 | 85.5443 | 86.9115 | 86.7083 | ✔ |
| 净资产收益率(%) | 20.61 | 21.51 | 5.04 | 10.03 | 15.08 | ✔ |
| 营业增长率(%) | 25.8916 | 33.7048 | 11.278 | 12.7922 | 14.5652 | ✔ |
| 净利润增长率(%) | 23.3295 | 31.1551 | 9.3894 | 9.9123 | 13.6462 | ✔ |
| 每股收益(%) | 1.1 | 1.2 | 0.29 | 0.5 | 0.8 | ✔ |
| 现金流量比率(%) | 111.2518 | 154.363 | 56.3201 | 121.584 | 101.7138 | ✔ |
| 三项费用比重(%) | 45.7413 | 45.6547 | 42.7477 | 43.6648 | 44.3461 | ✘ |
| 每股净资产(¥) | 5.3524 | 5.6017 | 5.9047 | 5.0025 | 5.3227 | ✔ |
| 流动比率(%) | 7.2462 | 9.0233 | 8.6904 | 8.5619 | 6.5238 | ✔ |
| 速动比率(%) | 6.8329 | 8.3735 | 8.0537 | 7.8646 | 6.0807 | ✔ |
| 现金比率(%) | 155.9856 | 203.9786 | 319.9569 | 344.3376 | 344.3376 | ✔ |
| 总资产利润率(%) | 20.1046 | 21.3409 | 4.6044 | 9.269 | 14.1208 | ✔ |
| 主营利润比重% | 329.9909 | 332.8944 | 298.7618 | 311.022 | 333.8953 | ✔ |
| 应收账款(万元) | 377,269.28 | 490,624.54 | 458,841.81 | 433,811.83 | 589,559.01 | ✘ |
| 应收票据(万元) | 65,887.00 | 52,855.67 | 42,160.81 | 11,542.36 | 69,098.40 | ✘ |
| 预付款项(万元) | 56,889.94 | 59,116.22 | 76,751.73 | 79,185.44 | 48,615.99 | ✔ |
| 存货(万元) | 103,057.37 | 160,680.59 | 174,491.07 | 193,659.84 | 173,684.87 | ✔ |
| 在建工程(万元) | 135,725.26 | 153,282.67 | 147,033.79 | 137,486.17 | 146,725.40 | ✔ |
| 应付款项(万元) | 138,120.92 | 128,924.68 | 139,374.42 | 148,229.91 | 148,150.69 | ✔ |
| 长期借款(万元) | -- | -- | -- | -- | -- | ✔ |
| 未分配利润(万元) | 1,311,501.33 | 1,654,760.54 | 1,786,303.14 | 1,730,793.71 | 1,890,461.20 | ✔ |
| 商誉(万元) | -- | -- | -- | -- | -- | ✔ |
| 流动资产(万元) | 429,183.75 | 524,517.07 | 534,752.03 | 589,954.68 | 696,617.10 | ✔ |
| 流动负债(万元) | 249,363.41 | 247,263.47 | 274,084.52 | 277,718.27 | 391,935.82 | ✔ |
恒瑞医药600276评分结果 | 84.85分 | 买入/增持 | ||||